Justin Zelin
Stock Analyst at BTIG
(1.80)
# 3,302
Out of 4,996 analysts
42
Total ratings
25%
Success rate
-1.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $25.57 | +388.85% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $2.47 | +183.40% | 3 | Sep 22, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $15.68 | +257.14% | 3 | Sep 19, 2025 | |
| IMAB I-Mab | Reiterates: Buy | $7 | $3.48 | +101.15% | 2 | Sep 10, 2025 | |
| VSTM Verastem | Reiterates: Buy | $20 | $8.89 | +124.97% | 2 | Sep 9, 2025 | |
| IBRX ImmunityBio | Initiates: Buy | $6 | $2.54 | +136.22% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $20.01 | +109.90% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.29 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $26.83 | +131.08% | 2 | Jul 9, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $1.85 | +548.65% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.47 | - | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $1.59 | +50,214.47% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $34.02 | +167.49% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.84 | +1,090.48% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.49 | +542.57% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $14.70 | +151.70% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $33.37 | +169.70% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $9.05 | +242.54% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $55.61 | -72.13% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $1.31 | +663.36% | 3 | Nov 16, 2022 |
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $25.57
Upside: +388.85%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $2.47
Upside: +183.40%
Syndax Pharmaceuticals
Sep 19, 2025
Reiterates: Buy
Price Target: $56
Current: $15.68
Upside: +257.14%
I-Mab
Sep 10, 2025
Reiterates: Buy
Price Target: $7
Current: $3.48
Upside: +101.15%
Verastem
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $8.89
Upside: +124.97%
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.54
Upside: +136.22%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $20.01
Upside: +109.90%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.29
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $26.83
Upside: +131.08%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $1.85
Upside: +548.65%
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.47
Upside: -
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.59
Upside: +50,214.47%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $34.02
Upside: +167.49%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.84
Upside: +1,090.48%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $2.49
Upside: +542.57%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $14.70
Upside: +151.70%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $33.37
Upside: +169.70%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $9.05
Upside: +242.54%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $55.61
Upside: -72.13%
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $1.31
Upside: +663.36%